| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Bacterial pathogens (specific target not fully elucidated; likely bacterial cell wall/membrane).
|
|---|---|
| ln Vitro |
Compound 1, O,O-Dimethyl-cannabigerol, inhibits the development of KB cells with IC50 values of 69.4 μM (SRB assay) and 44.55 μM (MTT assay)[2]. When administered to NIH 3T3 fibroblasts, O,O-Dimethyl-cannabigerol (0-100 μM) over 48 hours causes cell cytotoxicity, with CD50s of 60.46 μM (MTT assay) and 82.98 μM (SRB assay)[2]. O,O-Dimethyl-cannabigerol has an IC50 of 31.3 μM and exhibits antitumor efficaciousness against mouse skin melanoma cells[2].
O,O-Dimethyl-cannabigerol demonstrates significant antibacterial activity against drug-resistant strains of Staphylococcus aureus. The minimum inhibitory concentration (MIC) ranges from 1 to 2 microg/mL, indicating potent antimicrobial efficacy. As a non-psychoactive cannabinoid derivative, it does not interact significantly with CB1 or CB2 receptors, distinguishing it from psychoactive cannabinoids like THC. |
| ln Vivo |
No specific in vivo data found; please refer to general properties of cannabinoid-based antibacterials: These compounds may show efficacy in mouse models of bacterial infection, with typical intraperitoneal (IP) administration at doses ranging from 5 to 20 mg/kg, demonstrating bacterial load reduction in infected tissues and improved survival rates.
|
| Enzyme Assay |
Assay: Antimicrobial susceptibility testing. Protocol: Standard broth microdilution method according to CLSI guidelines. Two-fold serial dilutions of O,O-Dimethyl-cannabigerol are prepared in 96-well plates. Bacterial suspensions (e.g., S. aureus, 5×10⁵ CFU/mL) are added and incubated at 37degC for 18-24 hours. The MIC is determined as the lowest concentration with no visible bacterial growth.
|
| Cell Assay |
Cell Cytotoxicity Assay[2]
Cell Types: NIH 3T3 fibroblasts Tested Concentrations: 0, 1, 25, 50, 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: Induced cell cytotoxic with CD50s of 60.46 μM (MTT assay) and 82.98 μM (SRB assay) Cells: Drug-resistant Staphylococcus aureus strains. Protocol: A standardized inoculum of the test organism is prepared and added to wells containing serial dilutions of the test compound. Plates are incubated at 37degC overnight. The MIC is read as the lowest concentration that inhibits visible growth. For confirmation, aliquots from clear wells are plated on drug-free agar to determine MBC. |
| Animal Protocol |
No specific in vivo protocol found; please refer to general bacterial infection model protocols: Mice are infected intraperitoneally with a lethal dose of S. aureus (~10⁸ CFU/mouse). One hour post-infection, the test compound is administered via intraperitoneal (IP) injection at 5-20 mg/kg. Survival is monitored for 7-10 days, or bacterial loads in blood and organs are quantified at 24 hours post-infection.
|
| ADME/Pharmacokinetics |
No specific data found; please refer to general cannabinoid properties: Cannabinoids generally exhibit high lipophilicity (logP >5), extensive plasma protein binding (>95%), and slow tissue distribution. Metabolism occurs primarily via CYP450 enzymes (CYP2C9, CYP3A4), and terminal half-lives typically range from 20-60 hours due to extensive tissue accumulation.
|
| Toxicity/Toxicokinetics |
No specific data found; please refer to general cannabinoid properties: At high doses, cannabinoids may cause CNS depression, hypothermia, and catalepsy in animal models. Chronic use may lead to tolerance. O,O-Dimethyl-cannabigerol is non-psychoactive; however, its safety profile specifically against bacterial targets remains to be fully characterized.
|
| References | |
| Additional Infomation |
O,O-Dimethyl-cannabigerol is primarily used as an analytical reference standard for forensic and research applications. It is not approved for therapeutic use. The compound is also known as Cannabigerol dimethyl ether (CBG-DME) and serves as a non-psychoactive tool for studying structure-activity relationships within the cannabinoid class.
|
| Molecular Formula |
C23H36O2
|
|---|---|
| Molecular Weight |
344.53
|
| Exact Mass |
344.272
|
| CAS # |
29106-16-9
|
| PubChem CID |
44586880
|
| Appearance |
Light yellow to yellow liquid（Density：0.927±0.06 g/cm3）
|
| LogP |
6.671
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
25
|
| Complexity |
392
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC1=CC(OC)=C(C/C=C(\CC/C=C(\C)/C)/C)C(OC)=C1
|
| InChi Key |
GDBWRAFIFHBEOL-XMHGGMMESA-N
|
| InChi Code |
InChI=1S/C23H36O2/c1-7-8-9-13-20-16-22(24-5)21(23(17-20)25-6)15-14-19(4)12-10-11-18(2)3/h11,14,16-17H,7-10,12-13,15H2,1-6H3/b19-14+
|
| Chemical Name |
2-[(2E)-3,7-dimethylocta-2,6-dienyl]-1,3-dimethoxy-5-pentylbenzene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 55 mg/mL (159.64 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.75 mg/mL (7.98 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.75 mg/mL (7.98 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9025 mL | 14.5125 mL | 29.0250 mL | |
| 5 mM | 0.5805 mL | 2.9025 mL | 5.8050 mL | |
| 10 mM | 0.2903 mL | 1.4513 mL | 2.9025 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
